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Abstract
Background: Complex insertions and deletions (indels) from next-generation sequencing (NGS) data were prone to
escape detection by currently available variant callers as shown by large-scale human genomics studies. Somatic
and germline complex indels in key disease driver genes could be missed in NGS-based genomics studies.
Results: INDELseek is an open-source complex indel caller designed for NGS data of random fragments and PCR
amplicons. The key differentiating factor of INDELseek is that each NGS read alignment was examined as a whole
instead of “pileup” of each reference position across multiple alignments. In benchmarking against the reference
material NA12878 genome (n = 160 derived from high-confidence variant calls), GATK, SAMtools and INDELseek
showed complex indel detection sensitivities of 0%, 0% and 100%, respectively. INDELseek also detected all known
germline (BRCA1 and BRCA2) and somatic (CALR and JAK2) complex indels in human clinical samples (n = 8). Further
experiments validated all 10 detected KIT complex indels in a discovery cohort of clinical samples. In silico semi-
simulation showed sensitivities of 93.7–96.2% based on 8671 unique complex indels in >5000 genes from dbSNP
and COSMIC. We also demonstrated the importance of complex indel detection in accurately annotating BRCA1,
BRCA2 and TP53 mutations with gained or rescued protein-truncating effects.
Conclusions: INDELseek is an accurate and versatile tool for complex indel detection in NGS data. It complements
other variant callers in NGS-based genomics studies targeting a wide spectrum of genetic variations.
Keywords: Complex indel, Variant calling, Bioinformatics, Next-generation sequencing
Background
Complex insertions and deletions (indels) are a known
class of genetic variation [1] associated with human dis-
eases [2]. Simultaneous deletion and insertion of DNA
fragments of different sizes lead to net change in length.
No net change in length is also possible in case of
contiguous or non-contiguous multiple-nucleotide vari-
ants (MNV). Compared with lower-throughput Sanger
sequencing, analysis of next-generation sequencing data
relies more on bioinformatics algorithms for automated
variant calling. Of concern, recent studies revealed the
shortcomings of state-of-the-art variant callers that
might fail to detect somatic and germline complex indels
[3, 4]. Important mutations in key disease driver genes
could be missed in NGS-based genomics studies (e.g.
somatic CALR complex indels in myeloproliferative
neoplasms [5] and germline BRCA1/BRCA2 complex
indels in hereditary breast and/or ovarian cancer [6]).
Pindel-C [3] was introduced to detect the complex
indels missed by GATK [7] and VarScan [8] but the
implementation was not yet publicly available. Amplicon
Indel Hunter [9] and ScanIndel [10] were designed for
those that led to >5 bp net change in length or soft-
clipping, respectively. MAC [11] targeted MNV only by
analyzing single nucleotide variant (SNV) calls of primary
callers.
Here we present INDELseek, a software that directly
calls somatic and germline complex indels from Sequence
Alignment/Map (SAM/BAM) alignments regardless of
net change in length.* Correspondence: eskma@hksh.com
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Implementation
The INDELseek algorithm was implemented as a single
Perl script indelseek.pl that scans each NGS read
alignment and identifies closely spaced substitutions,
insertions or deletions in cis as potential complex indel
regardless of net change in length. The only external
dependency is SAMtools version 1.3 or above [12],
which supports sequencing depth exceeding 8000X in
case of deep amplicon sequencing. It was tested on both
CentOS Linux 5.5 and Cray XC30 supercomputer
(Extreme Scalability Mode) and can be run on the built-
in Perl 5 installation of any Linux/Unix-like environ-
ment. Alignments of NGS reads in the de facto SAM/
BAM format [12] serve as input while any complex indel
calls will be reported in variant call format (VCF)
version 4.1 [13].
INDELseek was designed to identify complex indel(s)
at single read level by examining each alignment as a
whole (Fig. 1). In contrast, mainstream NGS variant
callers examined each reference position across multiple
alignments (also known as “pileup”), losing the haplotype
information in case of multiple differences compared to
reference. Mainstream NGS read aligners (e.g. BWA-
MEM) usually align complex indels as multiple mis-
matches, insertions and/or deletions (Concise Idiosyncratic
Gapped Alignment Report (CIGAR) operations M, I and D,
respectively) clustered within a short window of reference/
read positions, which INDELseek was designed to detect.
Since CIGAR operation M could represent either match or
mismatch, it was first refined as operations = for match
and X for mismatch. INDELseek considers each window
fulfilling all of these criteria as a complex indel call: (1)
containing at least two X, I and/or D operations that are at
most l nucleotides away from each other; (2) length at least
two nucleotides. The parameter l is five by default and is
configurable through option –max_distance. For en-
hanced specificity, false positives can be marked and/or
removed based on configurable filters of read base quality,
allele frequency and allele depth.
INDELseek parameters were –skip_lowqual –ski-
p_lowdepth –skip_lowaf –min_af 0.2 for germline
BRCA1 and BRCA2 mutations, --skip_lowqual –ski-
p_lowdepth –skip_lowaf –min_af 0.02 for som-
atic CALR, JAK2 and KIT mutations, and
–skip_lowqual –skip_lowdepth –skip_lowaf
–max_distance 10 –min_af 0.2 –min_depth 20
for NA12878 whole-genome sequencing (WGS) dataset. A
single CPU core (2010 Intel Xeon X5660 2.8GHz) was
measured to be capable to process 56,000 alignments per
minute (275 bp MiSeq sequencing reads).
Fig. 1 INDELseek algorithm as illustrated by the BRCA2 complex indel of sample 2. Left: INDELseek directly reads NGS read alignments in the
standard SAM/BAM format. After refining matches and mismatches in the supplied alignments, clusters of closely spaced mismatches, insertions
and/or deletions are identified as potential complex indel calls. False positives are removed according to filters based on read base quality, allele
frequency and allele sequencing depth. Final complex indel calls are reported in the standard VCF format. Right: A representative BWA-MEM
alignment of a sample 2 NGS read was shown. The corresponding reference sequence (chr13:g.32912956_32912969) and base calls of the read
were shown above the below the alignment, respectively. In the alignment refinement step, M operators were refined as matches (=) and
mismatches (X). A cluster of closely spaced variants was identified as a potential complex indel call (highlighted as a red box). The complex
indel call passed the defined quality thresholds and was reported as a variant call in VCF format, which corresponds to the BRCA2 complex
indel c.4467_4474delinsTGTTTTT
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Results
We benchmarked complex indel detection performance of
GATK, SAMtools and INDELseek using an external WGS
dataset of the HapMap NA12878 genome (Illumina HiSeq
2000) and the corresponding high-confidence variant calls
from the Genome in a Bottle (GIAB) Consortium [14]. Al-
though the high-confidence variant calls did not comprise
complex indels as individual calls, we observed clusters of
closely spaced variants calls that appeared in cis in the
alignments of individual sequencing reads. Accordingly,
160 such loci from GIAB calls were manually curated as
putative complex indels (Additional file 1: Table S1) in the
intersection (total length 27 Mb) of GIAB high confidence
regions and Consensus Coding Sequence Project protein-
coding sequences and 10 bp intronic flanking regions [15].
We also observed closely spaced SNV that appeared in
trans in the alignments and 26 such loci were manually
curated as negative controls for complex indel detection
(Additional file 1: Table S2). SAMtools and GATK did not
call any complex indel from the putative GIAB complex
indels (0 of 160) and negative controls (0 of 26), demon-
strating 0% sensitivity and 100% specificity. The results
were concordant with recent studies that complex indels
were mostly missed by bioinformatics pipelines based on
common variant callers [3, 4]. INDELseek called all puta-
tive GIAB complex indels (160 of 160) and did not call any
from negative controls (0 of 26), demonstrating 100% sen-
sitivity and 100% specificity (Table 1). All three types of
complex indels resulting in net deletion of bases, no net
change in length, or net insertion of bases were detected
(Fig. 2a, b, c, respectively). In the context of complex indel
detection, the whole-alignment-based approach of INDEL-
seek was demonstrated to be superior to the conventional
“pileup” approach of common variant callers.
Next, we tested INDELseek using two different NGS
datasets of PCR amplicons (Table 1). INDELseek was
applied to a hereditary breast and/or ovarian cancer
(HBOC) panel dataset of 239 probands [6]. The 4-gene
panel targeted germline mutations (Illumina MiSeq). Prior
Sanger sequencing revealed that three of the probands
carried a unique pathogenic complex indel (BRCA1 n = 1
and BRCA2 n = 2) while remaining 236 probands were
negative for complex indel. INDELseek detected all three
complex indels (Table 2; Additional file 2: Figure S1-S3),
demonstrating 100% sensitivity and 100% specificity.
INDELseek was also applied to a myeloid neoplasm (MN)
panel dataset of 23 samples [16]. The 54-gene panel
targeted somatic mutations (Illumina MiSeq). From five
samples known to carry a unique complex indel (CALR
n = 4 and JAK2 n = 1), INDELseek detected all five com-
plex indels (Table 2; Additional file 2: Figure S4-S8).
The general applicability of INDELseek in complex
indel detection was further assessed using a wider
spectrum of complex indels, which showed different
combination of deletion and insertion lengths (375 combi-
nations) and different gene context (>5000 genes). We
collected 8671 unique complex indels from public data-
bases dbSNP and COSMIC for semi-simulation by in silico
engineering of complex indels in real NGS datasets. Base
quality scores were kept unchanged or similar to flanking
bases depending on the net gain in bases (0 or ≥1, respect-
ively). NGS data of NA12878, a BRCA1/BRCA2 complex
indel-negative sample, and a healthy adult were selected
for engineering from the WGS, HBOC and MN datasets,
respectively. INDELseek demonstrated sensitivities of
93.7% (8124 of 8671) for WGS, 96.2% (228 of 237) for
HBOC and 94.6% (545 of 576) for MN (Table 1).
As a discovery cohort, INDELseek was applied to an
additional MN panel dataset of 10 core-binding factor
leukemia samples that were clinically predicted to be
enriched for somatic mutations of KIT exon 8 [17]. A
total of 10 KIT in-frame complex indels were detected
from six of the samples (1 – 4 complex indels per
sample; Table 2) and verified by orthogonal validation
experiments (Additional file 2: Figure S9-S14).
Table 1 Evaluation of INDELseek complex indel detection
performance
Dataset Sample count
and description
Sensitivity Specificity
Real NGS data
1. Protein-coding and
flanking regions from
whole-genome
sequencing
(random fragments)
1 (NA12878) 100% 100%
160 putative
complex indels
26 negative
control loci
2. Hereditary breast
and/or ovarian
cancer panel
(amplicons)
239 100% 100%
3 positive samples
(BRCA1 n = 1,
BRCA2 n = 2)
236 negative
samples
3. Myeloid neoplasm
panel (amplicons)
23 100% 100%
5 positive samples
(CALR n = 4,
JAK2 n = 1)
18 negative samples
(NA12878 and 17
healthy controls)
Semi-simulated data by engineering mutations to real NGS data
1. Whole-genome
sequencing
(random fragments)
8671 collected from
COSMIC and dbSNP
93.7% N/A
2. Hereditary breast
and/or ovarian
cancer panel
(amplicons)
237 collected from
COSMIC and dbSNP
96.2% N/A
3. Myeloid neoplasm
panel (amplicons)
576 collected from
COSMIC and dbSNP
94.6% N/A
N/A Not applicable
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To demonstrate the importance of accurate complex
indel detection in clinical settings, we focused on 127 MNV
in HBOC genes (part of semi-simulation collection) and
compared their variant annotation results (Variant Effect
Predictor) in two scenarios: (1) original MNV and (2)
decomposing MNV into individual single-nucleotide vari-
ant for separate annotation, as if the MNV could not be
called as a haplotype. Comparison revealed marked differ-
ence in 11 (8.7%) MNV, which showed gained (n = 5) or
rescued (n = 6) protein-truncating effects (Table 3). With-
out accurate calling of complex indels, these MNV would
become false negative or false positive pathogenic muta-
tions, respectively. On the other hand, Variant Effect Pre-
dictor was tested to natively support complex indels called
by INDELseek in VCF format.
Conclusions
This study showed that common variant callers fail to
detect complex indels, a finding consistent with recent
studies [3, 4]. We also demonstrated that if complex
indels were called as individual variant calls (e.g. break-
ing down a single MNV to multiple SNV), the gained or
rescued protein-truncating effects will be mis-interpreted.
INDELseek was demonstrated as an accurate and versatile
complex indel caller, which is compatible with somatic
and germline genomics studies, NGS data of random frag-
ments and PCR amplicons, and all three classes of com-
plex indels (MNV, net insertion and net deletion). Since
INDELseek was implemented as a single Perl script that
directly reads SAM/BAM alignments and returns complex
indel calls in VCF format, it can be readily incorporated
into common bioinformatics workflows without any com-
pilation and installation. INDELseek complements other
common variant callers in academic and diagnostic NGS-
based genomics studies.
Methods
Benchmarking based on reference material
High-confidence variants calls and chromosomal regions of
NA12878 corresponded to the high-confidence genotype
version 2.19 [14]. Closely spaced variant calls were identi-
fied by BEDTools version 2.19.1 [18] (parameters: merge –
n –d 9). NA12878 200X whole genome sequencing dataset
was retrieved from Illumina Platinum Genomes [19].
a b c
Fig. 2 Types of complex indels detected by INDELseek. a Net deletion of bases (e.g. chr3:g.190106073_190106074delGGinsC). b No net change in
length (e.g. chr1:g.24201919_24201920delTTinsCC). c Net insertion of bases (e.g. chr15:g.41483633_41483636delCACCinsACACT). Corresponding
alignments of reference (Ref) and variant (Var) sequences are shown
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Table 2 Complex indels detected by INDELseek in human clinical samples
Sample Gene Mutation Allele frequency Sequencing
depth (X)
NGS method Orthogonal
validation
Germline pathogenic mutations in hereditary breast and/or ovarian cancers
1 BRCA1 c.4046_4047delinsA p.Thr1349Lysfs*17 37.9% 730 * †
2 BRCA2 c.4467_4474delinsTGTTTTT p.Lys1489Asnfs*15 74.9% 1272 * †
3 BRCA2 c.8400_8402delinsAAAA p.Phe2801Lysfs*11 33.6% 4141 * †
Somatic pathogenic mutations in myeloid neoplasms
4 CALR c.1102_1136delinsT p.Lys368Trpfs*51 40.8% 2274 ‡ †
5 CALR c.1154delAinsCTTGTC p.Lys385Thrfs*47 31.9% 2998 ‡ †
6 CALR c.1129_1154delinsTGTC p.Lys377Cysfs*46 73.6% 2159 ‡ †
7 CALR c.1118_1125delinsCTTG p.Asp373Alafs*56 15.3% 3603 ‡ §
8 JAK2 c.1620_1627delinsGA p.Ile540_Glu543delinsMetLys 57.7% 4629 ‡ †
9 KIT c.1248_1257delinsTTGG p.Thr417_Asp419delinsTrp 39.0% 11109 ‡ *
10 KIT c.1248_1256delinsTTTCCG p.Thr417_Asp419delinsPheArg 2.9% 13724 ‡ *
KIT c.1249_1258delinsGGATGGAACT p.Thr417_Arg420delinsGlyTrpAsnTrp 3.3% 13651 ‡ *
KIT c.1250_1258delinsAACCTC p.Thr417_Asp419delinsLysPro 11.9% 13525 ‡ *
KIT c.1251_1258delinsCTCCT p.Tyr418_Arg420delinsSerTrp 2.1% 13376 ‡ *
11 KIT c.1250_1256delinsT p.Thr417_Asp419delinsIle 5.7% 7326 ‡ §
KIT c.1251_1257delinsAACA p.Tyr418_Asp419delinsThr 2.2% 7416 ‡ §
12 KIT c.1251_1256delinsGGG p.Tyr418_Asp419delinsGly 2.7% 14829 ‡ *
13 KIT c.1253_1258delinsCCG p.Tyr418_Arg420delinsSerGly 40.7% 68180 ‡ *
14 KIT c.1256_1257delinsGTCTA p.Asp419delinsGlyLeu 17.9% 19042 ‡ *
*Microfluidic PCR and MiSeq sequencing
†Sanger sequencing
‡Probe extension/ligation and MiSeq sequencing
§PCR fragment analysis
Table 3 Gained or rescued protein-truncating effect of complex indels
Gene Genomic position Multiple-nucleotide variants (MNV) Predicted protein change
MNV called as a haplotype MNV called as separate single-nucleotide variants
Gained protein-truncating effect
BRCA2 13:32914101-32914102 c.5609_5610delTCinsAG p.Phe1870* p.Phe1870Tyr, p.Phe1870Leu
BRCA1 17:41245984-41245987 c.1561_1564delGCAGinsTAAA p.Ala521* p.Asp522Asn, p.Ala521Glu, p.Ala521Ser
BRCA1 17:41244552-41244553 c.2995_2996delCTinsTA p.Leu999* p.Leu999Gln, p.=
TP53 17:7578486-7578488 c.442_444delGATinsTGA p.Asp148* p.Asp148Glu, p.Asp148Gly, p.Asp148Tyr
TP53 17:7578286-7578287 c.562_563delCTinsTA p.Leu188* p.Leu188Gln, p.=
Rescued protein-truncating effect
TP53 17:7579366-7579368 c.319_321delTACinsCAA p.Tyr107Gln p.Tyr107*, p.Tyr107His
TP53 17:7578535-7578536 c.394_395delAAinsTG p.Lys132Trp p.Lys132Arg, p.Lys132*
TP53 17:7578433-7578434 c.496_497delTCinsGG p.Ser166Gly p.Ser166*, p.Ser166Ala
TP53 17:7578426-7578431 c.499_503delinsTACCT p. Gln167_His168delinsTyrLeu p.His168Leu, p.Gln167His, p.Gln167*
TP53 17:7578210-7578212 c.637_639delCGAinsTGG p.Arg213Trp p.=, p.Arg213*
TP53 17:7577508-7577509 c.772_773delGAinsTT p.Glu258Leu p.Glu258Val, p.Glu258*
Bold text indicates predicted protein truncation
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NA12878 myeloid neoplasm panel dataset (Illumina Tru-
Sight myeloid panel) was retrieved from Illumina BaseSpace
[20]. GATK HaplotypeCaller version 3.6 [7] and SAMtools
version 1.3 [12] with default parameters were used for vari-
ant calling. Concordance comparison of variant calls was
assisted by vcfeval tool of RTG Tools version 3.6.2 [21].
Germline complex indel detection in breast and/or
ovarian cancers
A total of 239 clinically high-risk breast and/or ovarian
cancer patients from Hong Kong Hereditary and High
Risk Breast Cancer Programme were selected for this
study. Patients were recruited from January 18, 2007 to
December 2, 2015 according to previously described
criteria [6]. Three patients carrying germline complex
indel mutation in either BRCA1 or BRCA2 (confirmed
by Sanger sequencing) were regarded as positive con-
trols. Another 236 patients either carrying pathogenic
mutation other than complex indel or not carrying any
pathogenic mutation in BRCA1 and BRCA2 (confirmed
by full gene Sanger sequencing) were regarded as nega-
tive controls. Complex indel detection by INDELseek
was performed on BWA-MEM (version 0.7.7) align-
ments of MiSeq NGS data of full BRCA1 and BRCA2
genes [6]. The definition of full BRCA1 and BRCA2
genes, sequencing methods, analysis methods and partial
results were reported previously [6].
Somatic complex indel detection in myeloid neoplasms
Twenty-two archival DNA samples were retrieved in
Hong Kong Sanatorium & Hospital from May 12, 2014
to February 3, 2016. Five of the DNA samples carried
somatic pathogenic CALR or JAK2 complex indels and
were regarded as positive controls. Remaining seventeen
DNA samples of healthy adults with normal complete
blood profile were regarded as negative controls as
described [16]. Ten core-binding factor leukemia DNA
samples were retrieved from Queen Mary Hospital,
Hong Kong from January 2003 to December 2014 as a
discovery cohort of KIT exon 8 mutations. A total of 32
DNA samples were screened by MiSeq sequencing of a
54-gene myeloid NGS gene panel as described [16, 17].
Complex indel detection by INDELseek was performed
on BWA-MEM (version 0.7.7) alignments of MiSeq
NGS data of CALR, JAK2 and KIT (exon 8 only).
In silico engineering of known complex indels to real NGS
data
Known complex indels were collected based on VCF files
from COSMIC v71 release [22] and dbSNP b146 release
[23]. MutationEngineer was developed to engineer muta-
tion into described real NGS data. Input is the variant of
interest and NGS read alignments (VCF and SAM formats,
respectively) and output is the engineered read alignments
(SAM format) for conversion to FASTQ sequencing reads.
Variant allele frequency of complex indel was engineered
to be 100%. Each complex indel was engineered as a separ-
ate set of FASTQ reads, which were analyzed in the same
way as real NGS data. Variants were annotated using Vari-
ant Effect Predictor version 75 [24]. Semi-simulation was
performed on a Cray XC30 supercomputer.
Orthogonal validation
BRCA1 and BRCA2 complex indels were confirmed by
conventional PCR and Sanger sequencing [6]. CALR
and JAK2 complex indels were confirmed by conven-
tional PCR and Sanger sequencing or conventional
PCR fragment analysis [5, 16]. KIT exon 8 complex
indels were confirmed by conventional PCR fragment
analysis [16] or microfluidic PCR followed by MiSeq
sequencing [25]. The primers used in these validation
studies were different from those used in the original
NGS datasets (Additional file 1: Table S3).
Reference sequences
Human reference genome sequence: GRCh37/hg19,
BRCA1: NM_007294.3, BRCA2: NM_000059.3, TP53:
NM_000546.4, PTEN: NM_000314.4, CALR: NM_004
343.3, KIT: NM_000222.2 and JAK2: NM_004972.3.
Variants were described according to the recommen-
dations of Human Genome Variation Society (HGVS)
[26]. Variant descriptions were checked by Mutalyzer
Name Checker [26].
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